Myelodysplasic syndromes: A comprehensive review

Blood Reviews

Volumn 19, Issue 6, 2005, Pages 301-319

  Catenacci, Daniel V T ^a   Schiller, Gary J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AML; Anemia; Arsenic; Azacytidine; Cytopenia; FAB WHO IPSS classification; MDS; Myelodysplasia; Targeted therapy

Indexed keywords

ARSENIC TRIOXIDE; AVASTATIN; BEVACIZUMAB; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOKINE; DARBOPOIETIN; DEXAMETHASONE; ERYTHROPOIETIN; ETANERCEPT; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMMUNEX; INFLIXIMAB; LENALIDOMIDE; MATRIX METALLOPROTEINASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; RAPAMYCIN; SEMAXANIB; SUNITINIB; TELOMERASE INHIBITOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; THYMOCYTE ANTIBODY; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BLEEDING; BONE MARROW; CHEMOTHERAPY; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CYTOGENETICS; CYTOPENIA; DEATH; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EVOLUTION; GENOMIC INSTABILITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; HUMAN; IMMUNOMODULATION; INFECTION RISK; MICROENVIRONMENT; MOLECULAR BIOLOGY; MOLECULAR CLONING; MYELODYSPLASIA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SOMNOLENCE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSFUSION;

EID: 25844495160     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2005.01.004     Document Type: Article

References (255)

1. P.J. Williamson, A.R. Kruger, P.J. Reynolds, T.J. Hamblin, and D.G. Oscier Establishing the incidence of myelodysplastic syndrome Br J Haematol 87 4 1994 743 745 (abstr)
2. C. Aul, U. Germing, Gattermann, and H. Minning Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 22 1 1998 93 100
3. C. Aul, A. Giangounidis, and U. Germing Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics Int J Hematol 73 4 2001 405 410 (abstr)
4. S.C. Finch Myelodysplasia and radiation Rad Res 161 2004 603 606
5. C. Nisse, J.M. Haguenoer, and B. Grandbastien Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France Br J Haematol 112 2001 927 935
6. S. Mundle, K. Allampallam, and K.A. Rashid Presence of activation-related m-RNA for EBV and CMV in the bone marrow of patients with myelodysplastic syndromes Cancer Lett 164 2001 197 205
7. M. Dalamaga, E. Petridou, F.E. cook, and D. Trichopoulos Risk factors for myelodysplastic syndromes: a case-control study in Greece Cancer Cause Control 13 2002 603 608
8. D. Rund, and D. Ben-Yehuda Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment Hematology 9 3 2004 179 187 (abstr)
9. M.L. Heaney, and D.W. Golde Myelodysplasia N Engl J Med 340 1999 1649 1660
10. J. Cortes CMML: a biologically distinct myeloproliferative disease Curr Hematol Rep 2 3 2003 202 208 (abstr)
11. J. Bennett The myelodysplastic/myeloproliferative disorders: the interface Hematol Oncol Clin North Am 17 5 2003 1095 1100 v. Review
12. J. Voglova, L. Chrobak, R. Neuwirova, V. Malaskova, and L. Straka Myelodysplatic and myeloproliferative type of chronic myelomonocytic leukemia distinct subgroups or two stages of the same disease Leuk Res 25 2001 493 499
13. M.W. Saif, J.L. Hopkins, and S.D. Gore Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia Leuk Lymph 43 11 2002 2083 2092 (abstr)
14. M. Giannouli, M. Voulgarelis, E. Zintzaras, A.G. Rzioufas, and H.M. Moutsopoulos Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study Rheumatology 43 2004 626 632
15. G. Chandran, M.J. Ahern, P. Seshadri, and D. Coghlan Rheumatic manifestations of the myelodysplastic syndromes: a comparative study Aust N Z J Med 26 5 1996 683 688 (abstr)
16. M. Steurer, S.M. Fritsche, and A. Tzankov Large-vessel arteritis and myelodysplastic syndrome: report of two cases Eur J Haematol 73 2004 128 133
17. F. Nakamura, Y. Kishimoto, T. Handa, Y. Arai, and K. Mitani Myelodysplastic syndrome with central diabetes insipidus manifesting hypodipsic hypernatremia and dehydration Am J Hematol 74 4 2004 213 216
18. K.F. Wong Hypoplastic myelodysplastic syndrome - a clinical, morphologic, or genetic diagnosis Cancer Genetics Cytogen 138 2002 85 88
19. P. Valent, C. Fonatsch, and R. Stindl Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype Leuk Res 28 6 2004 651 655
20. T. Chatterjee, A. Dixit, and M. Mohapatra Clinical, haematological and histomorphological profile of adult myelodysplastic syndrome. Study of 96 cases in a single institute Eur J Haematol 3 2004 93 97
21. E.P. Allesandrino, S. Amadori, and G. Barosi Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology Haematologica 97 12 2002 1286 1306
22. J.P. Maciejewski, and C. Selleri Evolution of clonal cytogenetic abnormalities in aplastic anemia Leuk Lymphoma 45 3 2004 433 440
23. P. Fenaux Myelodysplastic syndromes: from pathogenesis and prognosis to treatment Semin Hematol 41 2 Suppl. 4 2004 13 20
24. E. Hellstrom-Lindberg, C. Willman, and J. Barrett Achievements in understanding and treatment of myelodysplastic syndromes Hematology (Am Soc Hematol Educ Prog) 44 2000 110 132
25. A. Candoni, F. Silvestri, and S. Buonamici Targeted therapies in myelodyplastic syndrome: ASH 2003 review Semin Hematol Apr 41 2 Suppl. 4 2004 13 20
26. C. Rosenfeld, and A. List A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies Leukemia 14 2000 2 8
27. S. Faderi, and H.M. Kantarjian Novel therapies for myelodysplastic syndromes Cancer 101 20 2004 226 241
28. J.L. Gabrilove Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies The Oncologist 6 Suppl. 5 2001 4 7
29. L.J. Testa Apoptotic mechanisms in the control of erythropoiesis Leukemia 18 2004 1176 1199
30. Joseph Brazil, and P. Gupta Constitutive expression of the Fas receptor and its ligand in adult human bone marrow: a regulatory feedback loop for the homeostatic control of hematopoiesis Blood Cells Mol Dis 29 1 2002 94 103
31. M. Sawanobori, S. Yamaguchi, and M. Hasegawa Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes Leuk Res 27 2003 583 591
32. K. Sawada, K. Koizum, and T. Tarumi Role of physiologic concentrations of stem cell factor in leukemic type growth and myelodysplastic CD34+ cells Leuk Res 23 1999 1 11
33. Y. Saunthararajah, R. Nakamura, R. Wesley, Q.J. Wang, and A.J. Barrett A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome Blood 102 8 2003 3025 3027
34. J.P. Maciejewski, A.M. Ristiano, and A.M. Ristiano A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome Br J Haematol 117 2002 119 126
35. A.F. List Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies The Oncologist 6 Suppl. 5 2001 24 31
36. F.J. Giles The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies The Oncologist 6 Suppl. 5 2001 32 39
37. R.J. Klasa, A.F. List, and B.D. Cheson Rational approaches to design of therapeutics targeting molecular markers Hematol (Am Soc Hematol Educ Program) Jan 2001 443 462
38. C.S. Mitsiades, N. Mitsiades, and M. Koutsilieris The Akt pathway: molecular targets for anti-cancer drug development Curr Cancer Drug Targets 4 3 2004 235 256
39. A. Gallagher, F.L. Darley, and R. Padua The molecular basis of myelodysplastic syndromes Haematologica 82 1997 191 204
40. A. Ahmed, and T.O. Tollefsbol Telomerase, telomerase inhibition, and cancer J Anti-Aging Med 6 4 2003 315 325
41. K. Ohyashiki, H. Iwama, and N. Yahata Telomere dynamic in myelodysplastic syndromes and acute leukemic transformation Leuk Lymphoma 42 3 2001 291 299 (abstr)
42. M.H. Sheikhha, K. Tobal, and J.A. Liu Yin High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome Br J Haematol 177 2002 359 365
43. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 21 2003 2042 2054 Review
44. M. Teitell, and B. Richardson DNA methylation in the immune system Clin Immunol 109 2003 2 5
45. G. Leone, M.T. Voso, L. Teofili, and M. Lubbert Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS Clin Immunol 109 2003 89 102
46. S.K. Ma, C.T. Kong, and T.S. Wan Absence of microsatellite instability in primary myelodysplastic syndrome Int J Mol Med 5 2 2000 159 163
47. P. Karran, J. Offman, and M. Bignami Human mismatch repair, drug-induced DNA damage Biochimie 85 2003 1146 1160
48. INK4b expression and correlates with poor prognosis Leukemia 17 2003 919 924
49. INK4b gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation Br J Haematol 112 2001 148 154
50. L. Di Croce, V.A. Raker, and M. Corsaro Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor Science 295 2002 1079 1082
51. R. Morosetti, F. Grignani, and C. Liberatore Infrequent alterations of the rara gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes and cell lines Blood 87 10 1996 4398 4403
52. J.E. Lancet, and J.E. Karp Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy Blood 102 12 2003 3880 3889
53. B.D. Cheson The myelodysplastic syndromes Oncologist 2 1997 28 39
54. H.J. Olney, and M.M. LeBeau The cytogenetics of myelodysplastic syndromes Best Practice Res Clin Heamatol 14 3 2001 479 495
55. L.T. Washington, I. Jilani, E. Estey, and M. Albitar Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia Leuk Res 26 2002 899 902
56. N. Maurtizson, N. Albin, and L. Rylander Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001 Leukemia 16 12 2002 2366 2378
57. D.R. Head Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful? Curr Opin Oncol 14 1 2002 19 23
58. J.P. van Dijk, and T. de Witte Monitoring treatment efficiency in MDS at the molecular level Leuk Res 28 2004 101 108
59. M. Albitar, T. Manshouri, and Y. Shen Myelodysplastic syndrome is not merely preleukemia Blood 100 3 2002 791 798
60. A. Pellagatti, N. Esoof, and F. Watkins Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology Br J Haematol 125 5 2004 576 583
61. R.T. Silver, J.M. Bennett, and M. Deininger The second international congress on myeloproliferative and myelodysplastic syndromes Leuk Res 28 2004 979 985
62. P. Greenburg, J. Anderson, and T. de Witte Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS study group J Clin Oncol 18 19 2000 3447 3452
63. P. Multani, K. Tobinai, T. Kakizoe, J.O. Armitage, R. Ohno, and T. Sugimura Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features Jpn J Clin Oncol 32 9 2002 371 385
64. G.J. Schiller Myelodysplasia - therapeutic response to novel therapy and the need for new diagnostic groups Leukemia 17 2003 1183 1185
65. D.P. Steensma, and A. Tefferi The myelodysplastic syndrome (s): a perspective and review highlighting current controversies Leuk Res 27 2003 95 120
66. J.M. Bennett, D. Catovsky, and M.T. Daniel Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 1982 189 199
67. G. Tricot, M.A. Boogeaerts, C. De Wolf-Peeters, H. Van den Berghe, and R.L. Verwilghen The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations Br J Haematol 59 4 1985 659 670
68. G.F. Sanz, M.A. Sanz, and P.L. Greenberg Prognostic factors and scoring systems in myeldysplastic syndromes Haematologica 83 1998 358 368
69. W.L. Zhao, L. Xu, and W. Wu The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution The Hematol J 3 2002 137 144
70. J.J. Lee, H.J. Kim, and I.J. Chung Comparisons of prognostic scoring systems for myelodsyplastic syndromes: a Korean multicenter study Leuk Res 23 1999 425 432
71. W.R. Sperr, F. Wimazal, and M. Kundi Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems Ann Hematol 80 2001 272 277
72. P. Greenberg, C. Cox, and M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 6 1997 2079 2088
73. N.L. Harris, E. Jaffe, and J. Diebold The World health organization classification of hematological malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997 J Clin Oncol 17 12 1999 3835 3849
74. J.W. Vardiman, N.L. Harris, and R.D. Brunning The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 7 2002 2292 2302
75. M.L. Heaney, and D.W. Golde Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia Curr Oncol Rep 2 2 2000 140 143
76. U. Germing, N. Gattermann, C. Strup, M. Aivado, and C. Aul Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients Leuk. Res. 24 2000 983 992
77. K. Ohyashiki, J. Nishimaki, N. Shoji, K. Miyazawa, Y. Kimura, and J.H. Ohyashiki Re-evaluation of refractory anemia with excess blasts in transformation Leuk Res 25 2001 933 939
78. Y. Huh, I. Jilani, and E. Estey More cells in refractory anemia with excess blasts in transformation than in acute myeloid leukemia Leukemia 16 2002 2249 2252
79. C. Strupp, N. Gattermann, and A. Giagounidis Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals Leuk Res 27 2003 397 404
80. R.B. Howe, A. Porwit-MacDonald, R. Wanat, R. Tehranchi, and E. Hellstom-Lindberg The WHO classification of MDS does make a difference Blood 103 9 2004 3265 3270
81. J. Cermak, A. Vitek, and K. Michalova Combined statification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation Leuk Res 28 2004 551 557
82. M. Oosterveld, S.H. Wittebol, and W.A.J.G. Lemmens The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to international prognostic scoring system risk groups Br J Haematol 123 2003 81 89
83. N. Vey Arsenic trioxide for the treatment of myelodysplastic syndromes Expert Opin Pharmacother 5 3 2004 613 621
84. W. Verbeek, and A. Ganser Evolving treatment options of myelodysplastic syndromes Ann Hematol 80 2001 499 509
85. A.F. List New approaches to the treatment of myelodysplasia The Oncologist 7 Suppl. 1 2002 39 49
86. G. Mufti, A.F. List, S.D. Gore, and A.Y. Ho Myelodysplastic syndrome Hematology (Am Soc Hematol Soc Program) 2003 176 199
87. [no aurthors listed] NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network. Oncology (Huntingt). 1998;12(11A):53-80.
88. B.D. Cheson, J.M. Bennett, and H. Kantarjian Myelodysplastic syndromes standardized response criteria: further definition Blood 98 6 2001 1985
89. F. Pisani, and A. Rainaldi Management of high-risk myelodysplastic syndromes Crit Rev Oncol Hematol 131 2 2001 125 134
90. V.S. Blinder, and G.J. Roboz Hematopoietic growth factors in myelodysplastic syndromes Curr Hematol Rep 2 6 2003 453 458
91. H.I. Saba Myelodysplastic syndromes in the elderly: the role of growth factors in management Leuk Res 20 3 1996 203 219
92. R.S. Stein The role of erythropoietin in the anemia of myelodysplastic syndrome Clin Lymphoma 4 Suppl. 1 2003 S36 S40
93. P. Greenberg, and K. Taylor Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS) Blood 82 Suppl. 1 1993 196a
94. E. Hellstrom-Lindberg, N. Gulbrandsen, and G. Lindberg A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life Br J Haematol 120 2003 1037 1046
95. N. Casadevall, P. Durieux, and S. Dubois Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial Blood 104 2 2004 321 327
96. R. Kurzrock, J. Cortes, D.A. Thomas, S. Jeha, S. Pilat, and M. Talpaz Pilot study of low-dose interleukin-11 in patients with bone marrow failure J Clin Oncol 19 21 2001 4165 4172
97. I. Tepler, L. Elias, and J.W. Smith A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy Blood 87 1996 3607 3614
98. R. Stasi, M. Brunetti, and S. Buss Serum levels of tumour necrosis factor-alpha resonse to recombinant human erythropoietin in patients with myelodysplastic syndrome Clin Lab Haematol 19 3 1997 197 210
99. M. Benesch, and J. Deeg Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders Mayo Clin Proc 78 2003 981 990
100. Editorial. Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "When"? Mayo Clin Proc 2003;78:941-943.
101. J. Sierra, W.S. Perez, and C. Rozman Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia Blood 100 6 2002 1997 2004
102. C.S. Cutler, S.J. Lee, and P. Greenberg A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 2 2004 579 585
103. H. Castro-Malaspina, R.E. Harris, and J. Gajewski Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in510 transplants facilitated by the National Marrow Donor Program Blood 99 6 2002 1943 1951
104. B. Stewart, M. Verdugo, K.A. Guthrie, F. Appelbaum, and H.J. Deeg Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes Br J Haematol 123 2003 879 885
105. G.W. Chan, F.M. Foss, A.K. Klein, K. Sprague, and K.B. Miller Reduce-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission and less graft-versus-host disease Biol Blood Marrow Transplant 9 2003 753 759
106. N. Kroger, R. Brand, and A. van Biezen Autologous setm cell transplantation for treatment related MDS/AML. A report of the Chronic Leukemia Working Party (CLWP) Blood 102 2003 43a
107. T. de Witte, S. Suciu, and G. Verhoef Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS Blood 98 8 2001 2326 2331
108. M.E. Parker, T. Shafi, and A. Pagluica Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim reulsts of outcome following reduced-intensity conditioning compared with standard preparative regimens Br J Haematol 119 2002 144 154
109. M. Bornhauser, B. Storer, and J.T. Slattery Conditioning with fludariabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells Blood 102 3 2003 820 826
110. J. Gabrilove Hematologic malignancies: an opportunity for targeted drug therapy The Oncologist 6 Suppl. 5 2001 1 3
111. P. Musto Thalidomide therapy for myelodysplastic syndromes: current status and future prospectives Leuk Res 28 2004 325 332
112. F. Zorat, V. Shettey, and D. Dutt The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes Br J Haematol 115 2001 881 884
113. A. Raza, P. Meyer, and D. Dutt Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodyspalstic syndromes Blood 98 4 2001 958 965
114. C. Strupp, U. Germing, M. Alvado, E. Misgeld, R. Haas, and N. Gattermann Thalidomide for the treatment of patients with myelodysplastic syndromes Leukemia 16 2002 1 6
115. M. Offidani, L. Corvatta, and M. Marconi Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose minimizing peripheral neuropathy Eur J Haematol 72 2004 403 409
116. A.F. List, S. Kurtin, and B. Glinsman-Gibson Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS) Blood 102 2003 795 801
117. K.H. Antman Introduction: the history of arsenic trioxide in cancer therapy The Oncologist 6 Suppl. 2 2001 1 2
118. S. Waxman, and K.C. Anderson History of the development of arsenic derivatives in cancer therapy The Oncologist 6 Suppl. 2 2001 3 10
119. H.D. Sun, L. Ma, and X.C. Hu Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of tradition Chinese Medicine Chin J Comb Trad Chin Med West Med 12 1992 170 171
120. 3) in the treatment of acute promyelocytic leukemia (APL). Clinical efficacy and pharmacokinetics in relapsed patients Blood 89 1997 3354 3360
121. S.L. Soignet, P. Maslak, and Z.-G. Wang Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N Engl J Med 339 19 1998 1341 1348
122. A.J. Murgo Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the national cancer institute cooperative research and development studies The Oncologist 6 Suppl. 2 2001 22 28
123. A.F. List, M. Beran, and J. Dipersio Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes Leukemia 17 2003 1499 1507
124. A.M. Evens, M.S. Tallman, and R.B. Gartenhaus The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future Leuk Res 28 2004 891 900
125. D.M. Rust, and S.L. Soinget Risk/benefit profile of arsenic trioxide The Oncologist 6 Suppl. 2 2000 29 32
126. A. Donelli, C. Chiodino, and R. Panissidi Might arsenic triodxide be useful in the treatment of advanced myelodysplastic syndromes Haematologica 85 2000 1002 1003
127. S. Parmar, L.M. Rundhaugen, and L. Boehlke Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old Leuk Res 28 2004 909 919
128. J.J. Molldrem, M. Caples, D. Mavroudi, M. Plante, N.S. Young, and A.J. Barrett Antithymocyte globulin for patients with myelodysplastic syndrome Br J Haematol 99 1997 699 705
129. S.B. Killick, G. Mufti, and J.D. Cavenagh A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low risk' myelodysplasia Br J Haematol 120 2003 679 684
130. S. Yazji, F.J. Giles, and A.-M. Tsimberidou Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes Leukemia 17 2003 2101 2106
131. M. Stadler, U. Germing, and K.-O. Kliche A prospective, randomized, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes Leukemia 18 2004 460 465
132. D.P. Steensma, Dispenzieri, S. Breanndan-Moore, G. Schroeder, and A. Tefferi Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome Blood 101 6 2003 2156 2158
133. J.J. Molldrem, E. Leifer, and E. Bahceci Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes Ann Intern Med 137 2002 156 163
134. T. Yamada, H. Tsurumi, S. Kasahara, T. Hara, M. Sawada, and H. Moriwaki Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A J Cancer Res Clin Oncol 129 2003 485 491
135. C. Selleri, J.P. Maciejewski, and L. Catalano Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia Cancer 95 9 2002 1911 1922
136. T. Shimamoto, K. Tohyama, and T. Okamoto Cyclosporin: a therapy for patients with myelodysplastic syndrome:multicenter pilot studies in Japan Leuk Res 27 2003 783 788
137. H.L. Tai Technology evaluation: Valspodar, Novartis AG Curr Opin Mol Ther 2 4 2000 459 467
138. J.-T. Lin, W.-S. Wang, and C.-C. Yen Myelodysplastic syndrome complicated by autoimmune haemolytic anemia: remission of refractory anemia following mycophenolate mofetil Ann Hematol 81 2002 723 726
139. A. Raza, H. Qawi, and L. Lisak Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone Blood 95 5 2000 1580 1587
140. A. Raza, H. Qawi, and T. Andric Pentoxifylline, ciprofloxacin and dexamethasone improve the ineffective hematopoiesis in myelodysplastic syndrome patients; malignancy Hematol 5 4 2000 275 284
141. N. Novitzky, R. Mohamed, J. Finlayson, and C. Du Toit Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes Exp Hematol 28 2000 941 949
142. J. Braun, and J. Sieper Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases Exp Opin Biol Ther 3 1 2003 141 168
143. R. Stasi, and S. Amadori Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes Br J Haematol 116 2002 334 337
144. A. Raza, L.A. Lisak, and Tahir Hematologic improvement in response to anti-tumor necrosis factor (TNF) therapy with Remicade in patients with myelodysplastic syndrome (MDS) Blood 100 2003 795 (abstr)
145. Greenberg Treatment of myelodysplastic syndrome with agents interfering with inhibitory cvtokines Annal Rheumatic Dis 60 11 2001 41 42
146. H.J. Deeg, J. Gotlib, and C. Beckham Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study Leukemia 16 2002 162 164
147. C.S. Rosenfeld, and C. Bedell Pilot study of recomvinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome Leuk Res 26 8 2002 721 724
148. A.F. List, S. Kurtin, and N. Callander Randomized, double-blind Phase II study of the matrix metalloproteinase (MMP) inhibitor, AG3340 (prinomastat) in patients with myelodysplastic syndrome Blood 100 2002 789a
149. K. Arimura, N. Arima, and K. Matsushita Matrix Metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA Eur J Haematol 73 1 2004 17 24
150. H.I. Hurwitz Introduction: targeting angiogenesis in cancer therapy The Oncologist 9 Suppl. 1 2004 1
151. N. Ferrara Vascular endothelial growth factor as a target of anticancer therapy The Oncologist 9 Suppl. 1 2004 2 10
152. A. Aguayo The role of angiogenesis in the biology and therapy of myelodysplastic syndromes Curr Hematol Rep 3 3 2004 184 191
153. T.M. Moehler, J. Hillengass, H. Goldschmidt, and A.D. Ho Antiangiogenic therapy in hematologic malignancies Curr Pharm Des 10 11 2004 1221 1234
154. A. Aguayo, H.M. Kantarjian, and E.H. Estey Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes Cancer 95 2002 1923 1930
155. Q. Hu, A.L. Dey, and Y. Yang Soluble vascular endothelial growth factor receptor 1, and not factor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes Cancer 100 2004 1884 1891
156. H.X. Chen Expanding the clinical development of bevacizumab The Oncologist 9 Suppl. 1 2004 27 35
157. E. Bergsland, and M.N. Dickler Maximizing the potential of bevacizumab in cancer treatment The Oncologist 9 Suppl. 1 2004 36 42
158. J. Gotlib, C.H.M. Jamieson, and A. List Phase II study of bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): preliminary results Blood 102 2003 425a
159. A.-M. O'Farrell, H.A. Yuen, and B. Smolich Effects of SU5416, a small molecule tyrosine kinase recpetor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia Leuk Res 28 2004 679 689
160. F.J. Giles, M.A. Cooper, and L. Silverman Phase II study of SU5416 - small molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases Cancer 97 2003 1920 1928
161. F.J. Giles, A.T. Stopeck, and L.R. Stiverman SU5416, a small molecule tyrosine kinase recpetor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood 102 2003 795 801
162. G.J. Roboz, A.F. List, and F.J. Giles Phase I trial of PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in acute myeloid leukemia and myelodysplastic syndrome Blood 102 2003 361a
163. A.L. Thomas, B. Morgan, and J. Drevs Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK222584 Semin Oncol 30 3 Suppl. 6 2003 32 38
164. L.R. Kellan Telomerase: biology and phase I trials Lancet Oncol 2 2001 95 102
165. M. Ladetto, M. Ciompagno, and I. Ricca Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders Blood 104 12 2004 4644 4649
166. A. Roth, S. Verauteren, H.J. Sutherland, and P.M. Lansdorp Telomerase is limiting the growth of acute myeloid leukemia cells Leukemia 17 2003 2410 2417
167. A. Nakajima, T. Tauchi, and G. Sashida Telomerase inhibition enhaves apoptosis in human acute leukemia cells: possibility of antitelomerase therapy Leukemia 17 2003 560 567
168. T. Tauchi, K. Shin-ya, and G. Sashida Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells:involvement of ATM-dependent DNA damage response pathways Oncogene 22 2003 5338 5347
169. M. Sumi, T. Tauchi, and G. Sashida A G-quadriplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia Int J Oncol 24 6 2004 1481 1487
170. L.R. Silverman Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS) The Oncologist 6 Suppl. 5 2001 8 14
171. G. Leone, L. Teofili, M.T. Voso, and M. Lubbert DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias Haematolocia 87 2002 1324 1341
172. J. Gryn, Z.R. Zeigler, and R.K. Shadduck Treatment of myelodysplastic syndromes with 5-azacytidine Leuk Res 26 2002 893 897
173. [No authors listed] Decitabine: 2′-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NDS 127716. Drugs R D. 2003;4(6):352-8.
174. R. Brown, and J.A. Plumb Demethylation of DNA by decitabine in cancer chemotherapy Exp Rev Anticancer Ther 4 4 2004 501 510 (abstr)
175. L.R. Silverman, J.F. Holland, and R.S. Weinberg Effects of treatment with 5-Azacytidine on the in vivo and in vitro hematopoiesis in patients with meyledysplastic syndromes Leukemia 7 Suppl. 1 1993 21 29
176. L.R. Silverman, J.F. Holland, and R.B. Davis Azacytidine induces trilineage responses in patients with myelodysplastic sydndromes: the cancer and leukemia group B experience Haematologica 76 1991 42
177. L.R. Silverman, E.P. Demakos, and B.L. Peterson Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 2002 2429 2440
178. A.B. Kornblith, J.E. Herndon II, and L.R. Silverman Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial:a Cancer and Leukemia Group B study J Clin Oncol 20 10 2002 2441 2452
179. J.-P. Issa, G. Garcia-Manero, and F.J. Giles Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 5 2004 1635 1640
180. J. van den Bosch, M. Lubbert, G. Verhoef, and P.W. Wijermans The effects of 5-aza-2′-deoxycytidine (decitabine)on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes Leuk Res 28 2004 785 790
181. M. Deskalakis, T.T. Nguyn, C. Nguyen, P. Guldberg, G. Kohler, and P. Wijermans Demethylation of a hypomethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment Blood 100 8 2002 2957 2964
182. V. Zagonel, G. Lo re, and G. Marotta 5-Aza-2′deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes Leukemia 7 Suppl. 1 1993 30 35
183. P.W. Wijermans, J.W. Krulder, and P.C. Huijgens Continuos infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome Leukemia 11 1997 1 5
184. P.W. Wijermans, M. Lubbert, and G. Verhoef Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly J Clin Oncol 18 2000 956 962
185. P. Wijermans, M. Lubbert, and G. Verhoef Low dose Decitibine for elderly high risk MDS patients: who will respond? Blood 100 Suppl. 1 2002 355
186. X. Lopez-Karpovitch, O. Barrales-Benitez, M. Flores, and J. Piedras Effect of Azacytidine in the release of leukemia inhibitory factor, oncostatin M, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia Cytokine 20 4 2002 154 162
187. P.W. Wijermans, M. Lubbert, and G. Verhoef LDH is an important risk factor to predict survival in patients with MDS treated with 5-aza-2′-deoxycytidine (decitabine) Blood 102 2003 424 (abstr)
188. A. Burgess, A. Ruelfi, and H. Beamish Histone deacetylase inhibitors specifically kill nonproliferating tumour cells 2004 Oncogene Advance Publication p. 1-9
189. R. Somech, S. Izraeli, and A. Simn Histone deacetylase inhibitors - a new tool to treat cancer Cancer Treat Rev 30 5 2004 461 472
190. R. Kristeleit, L. Stimson, P. Workman, and W. Aherne Histone modification enzymes: novel targets for cancer drugs Exp Opin Emerg Drugs 9 1 2004 135 154
191. Marks PA, Richon VM, Kelly WK, et al. Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp 2004;259:269-81; discussion 281-8.
192. A. Kuendgen, C. Strupp, and M. Aivado Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans tretinoic acid Blood 104 5 2004 1266 1269 Epub 2004 May 20
193. R. Tang, A.M. Faussat, and P. Majdak Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1 Leukemia 18 7 2004 1246 1251
194. J. Karp, S.H. Kaufmann, A.A. Adjeir, J.E. Lancet, J.J. Wright, and D.W. End Current staturs of clinical trials of farnesyltransferase inhibitors Curr Opin Oncol 13 2001 470 476
195. J.E. Karp, and J.E. Lancet Farnesyltransferase Inhibitors (FTIs) in myeloid malignancies Ann Hematol 83 Suppl. 1 2004 587 588
196. R. Kurzrock, H. Kantarjian, and J. Cortes Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting Blood 102 13 2003 4527 4534
197. J.E. Lancet, J.D. Rosenblatt, and J.E. Karp Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias Semin Hematol 39 3 Suppl. 2 2002 31 35
198. J.L. Liesveld, J.E. Lancet, and Ke Rosell Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis Leukemia 17 2003 1806 1812
199. R. Kurzrock, M. Albitar, and J.E. Cortes Phase II Study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome J Clni Oncol 22 2004 1287 1292
200. R. Kurzrock, J. Cortes, and H. Kantarjian Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome Semin Hematol 39 4 Suppl. 3 2002 20 24
201. V. Santini Amifostine: chemotherapeutic and radiotherapeutic protective effects Exp Opin Pharmacother 2 3 2001 479 489
202. R. Ivernizzi, A. Pecci, and Travaglino Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes Br J Haematol 118 2002 246 250
203. P.G. Richardson, T. Hideshima, C. Mitsiades, and K. Anderson Proteasome inhibition in hematologic malignancies Ann Med 36 4 2004 304 314
204. R.J. Klasa, A.F. List, and B.D. Cheson Rational approaches to design of therapeutics targeting molecular markers Hematology (Am Soc Hematol Educ Program) 44 2001 443 462 Review
205. M.R. Bishop, P.L. Iverson, and E. Bayever Phase I trial of an antisense oligonucleotide OL91 p53 in hematologic malignancies J Clin Oncol 14 4 1996 1320 1326
206. Fonarow GC. Aggressive treatment of atherosclerosis: the time is now. Cleve Clin J Med. 2003 May;70(5):431-4, 437-8, 440. Review.
207. J. Cortes, and H. Kantarjian A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome Cancer 97 2003 1234 1241
208. T. Prebet, S. Ducastelle, and S. Debotton A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes The Hematol J 5 2004 209 215
209. G.J. Ossenkoppele, W.J. Graveland, and P. Sonneveld The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients Blood 103 8 2004 2908 2913
210. P.L. Greenberg, S.J. Lee, and R. Advani Mitoxantrone, etopiside, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) J Clin Oncol 22 6 2004 1078 1086
211. A. Raza, S. Buonamici, and L. Lisak Arsenic trioxide and thalidomide combination produces multi-lineage haematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression Leuk Res 28 2004 791 803
212. M.R. Weihrauch, P. Staib, B. Seiberlich, M. Hoffmann, V. Diehl, and H. Tesch Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia Leuk Lymph 45 4 2004 699 704
213. W.K. Hofmann, G. Heil, and C. Zander Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia Ann Hematol 83 2004 498 503
214. M.R. Acharya, and W.D. Figg Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucloeside analogue Cancer Biol Ther Advance Publication 3 8 2004
215. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with Fludarabine, Mitoxantrone, Dexamethasone(FND) plus Rituximab and Interferon Alfa. Blood. 2005. Mar 1; [Epub ahead of print].
216. M. Voulgarelis, S. Giannouli, K. Ritis, and A.G. Tzioufas Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts Eur J Clin Invest 34 10 2004 690 700
217. L. Malcovati, M.G. Della Porta, and M. Lunghi Flow Cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome Leukemia Mar 24 2005 Epub ahead of print
218. B.L. Wood Flow cytometric diagnosis of myelodysplasia and myeloproliferative disorders J Biol Regul Homeost Agents 18 2 2004 141 145
219. S. Cherian, J. Moore, and A. Bantly Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes Cytometry B Clin Cytom 64 1 2005 9 17
220. A. Martinez-Ramirez, M. Urioste, and L. Melchor Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array Genes Chromosomes Cancer 42 3 2005 287 298
221. E. Barouk-Simonet, V. Soenen-Cornu, and C. Roumier Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases Cancer Genet Cytogenet 157 2 2005 118 126
222. M.K. Andersen, D.H. Christiansen, and J. Peersen-Bjergaard Centromeric breakage and highly rearranged chromosome derivatives associated with mutations TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study Genes Chromosomes Cancer 42 4 2005 358 371
223. J.L. Liesveld, C.T. Jordan, and G.L. Phillips 2nd The hematopoitic stem cell in myelodysplasia Stem Cells 22 4 2004 590 599
224. Chan EM, Comer EM, Brown FC, et al. AML1-FOG2 Fusion Protein in Myelodysplasia. Blood. 2005 Feb 10; Epub ahead of print.
225. X. Li, and Q. Pu Megakaryocytopoiesis and apoptosis in patients with myelodysplastic syndromes Leuk Lymphoma 46 3 2005 387 391
226. Flores-Figueroa E, Arana-Trejo RM, Gutierrez-Espindola G, et al. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization.
227. N. Panoskaltsis Dendritic cells in MDS and AML - cause, effect or solution to the immune pathogenesis of disease? Leukemia 19 3 2005 354 357
228. W.G. Kearns, J.F. Sutton, and J.P. Maciejewski Genomic instability in bone marrow failure syndromes Am J Hematol 76 3 2004 220 224
229. Claessens YE, Park S, Dubart-Kupperschmitt A, et al. Rescue of early stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant negative form of FADD. Blood 2005. Jan 27; Epub ahead of print.
230. D. Campioni, P. Secchiero, and F. Corallini Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes Am J Pathol 166 2 2005 557 563
231. M.G. Alexandrakis, F.H. Passam, and D.S. Kyriakou Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes J Mol Histol 35 8-9 2004 857 863
232. M.L. Loh, S. Martinelli, and V. Cordeddu Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia Leuk Res 29 4 2005 459 462 Epub 2004 Dec 30
233. Craven SE, French D, Ye W, et al. Loss of hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndromes. Blood. 2005 Jan 13; Epub ahead of print.
234. Wolfler A, Erkland SJ, Bodner C, et al. A functional single nucleotide polymorphism of the G-CSF receptor gene predisposes to high-risk myelodysplastic syndrome. Blood 2005. Jan 11; Epub ahead of print.
235. K. Saunders, B. Czepulkowski, and R. Sivalingam Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes Cancer Genet Cytogenet 156 2 2005 154 157
236. D.P. Steensma, R.J. Gibbons, and R.A. Mesa Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia Eur J Haematol 74 l 2005 47 53
237. M.K. Andersen, D.H. Christiansen, and J. Pedersen-Bjergaard Amplification or duplification of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML Leukemia 19 2 2005 197 200
238. A.A. Giagounidis, U. Germing, J.S. Wainscoat, J. Boultwood, and C. Aul The 5q- syndrome Hematology 9 4 2004 271 277
239. W. Tse, H. Joachim Deeg, and D. Stirewaite Increased AF1q gene in high-risk myelodysplastic syndrome Br J Haematol 128 2 2005 218 220
240. C.H. Dunphy Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes Arch Pathol Lab Med 129 2 2005 219 222
241. A.I. Cabello, R. Collado, and M.A. Ruiz A retrospective analysis of myelodysplastic syndromes with thrombocytosis: rectification of the cases by WHO proposals Leuk Res 29 4 2005 365 370 Epub 2004 Dec 2
242. J. Cermak, M. Belickova, and H. Krejcova The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia Leuk Res 29 4 2005 371 379 Epub 2004 Dec 22
243. D. Marisavljevic, Z. Rolovic, D. Boskovic, and M. Colovic Long-term survivors in myelodysplastic syndromes: clinical and biological characteristics Med Oncol 21 4 2004 333 338
244. D. Marisavljevic, Z. Rolovic, and V. Cemerikic Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance Med Oncol 21 4 2004 325 331
245. P. Musto, F. Lanza, and E. Balleari Darbopoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes Br J Haematol 128 2 2005 204 209
246. R.S. Komrokji, and G.H. Lyman The colony-stimulating factors: use to prevent and treat neutropenia and its complications Expert Opin Biol Ther 4 12 2004 1897 1910
247. R. Wong, M. Shahjahan, and X. Wang Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation Biol Blood Marrow Transplant 11 2 2005 108 114
248. K. Nakai, Y. Kanda, and S. Fukuhara Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome Leukemia 19 3 2005 396 401
249. D. Bowen, L. MacIlwaine, and J. Cavanagh Thalidomide therapy for low-risk Myelodysplasia Leuk Res 29 2 2005 235 236
250. A. List, S. Kurtin, and D.J. Roe Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 6 2005 549 557
251. U. Plazbecker, M. Haase, and R. Herbst Activity of sirolimus in patients with myelodysplastic syndrome - results of a pilot study Br J Haematol 128 5 2005 625 630
252. [No authors listed] Azacitidine (vidaza) for myelodysplastic syndrome. Med Lett Drugs Ther 2005 Jan 31;47(1201):11.
253. T.E. Coyle, A.K. Bair, and C. Stein Acute leukemia associated with valproic acid treatment: A novel mechanism for leukemogenesis Am J Hematol 78 4 2005 256 260
254. Cortes J, Faderi S, Estey E, et al. Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes. J Clin Oncol. 2005 Feb 22; Epub ahead of print.
255. Giagounidis AA, Haase S, Germing U, et al. Treatment of myelodysplastic syndrome with isolated del (5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Ann Hematol. 2005 Mar 23; Epub ahead of print.